386 filings
Page 9 of 20
8-K
0b3l2mrs
28 Mar 17
Other Events
12:00am
8-K
pvd6pyyl 2q044rqehcl
13 Mar 17
Cempra Retains Morgan Stanley to Lead Review of Strategic Business Options
12:00am
8-K
4schnp8o2q
6 Mar 17
Regulation FD Disclosure
12:00am
POS AM
z7gjp
2 Mar 17
Prospectus update (post-effective amendment)
12:00am
8-K
nihg1jz45wpno66zm
28 Feb 17
Cempra Provides Corporate Update and Reports Fourth
12:00am
POSASR
piuqyjiwwcle23smyhgj
27 Feb 17
Automatic shelf registration (post-effective amendment)
12:00am
8-K
9sm85niyd6ug
24 Feb 17
Cempra’s Fusidic Acid Achieves Primary Endpoint In Phase 3 Study of Absssi
12:00am
8-K
o2ey54i
9 Jan 17
Regulation FD Disclosure
12:00am
8-K
o7efx3v2dqsxt bbcx
29 Dec 16
CEMPRA RECEIVES COMPLETE RESPONSE LETTER FROM FDA FOR SOLITHROMYCIN NDAs
12:00am
8-K
0aualvrgg
12 Dec 16
Cempra Appoints DR. David Zaccardelli As Acting Chief Executive Officer, Promotes Chief Commercial Officer David Moore to President
12:00am
8-K
jd7jc
5 Dec 16
Begins Phase 3 Studies In Japan with Cempra’s Solithromycin
12:00am
8-K
o1ssg raax5
15 Nov 16
Regulation FD Disclosure
12:00am
8-K
vvmd2ztxc5j2bz
10 Nov 16
Other Events
12:00am
8-K
8pgos8p29zjw3eb
7 Nov 16
Fda Advisory Committee Votes That Efficacy Results of
12:00am
8-K
b9zukia no
1 Nov 16
Cempra Receives $10 Million Milestone Payment from
12:00am
8-K
2blrd8
27 Oct 16
Cempra Reports Third Quarter 2016 Financial Results and Provides
12:00am
8-K
v68zr hbx8dy
30 Sep 16
Interim Results from Phase 2 Study
12:00am